Merck KGaA Unveils New Data on Multiple Sclerosis Treatment Efficacy at ECTRIMS 2025 Congress

Merck KGaA will present over 30 abstracts on its multiple sclerosis (MS) portfolio at the ECTRIMS 2025 Congress. Four-year Phase 4 data confirm the sustained efficacy of MAVENCLAD (cladribine tablets) in RRMS patients, with 83.4% experiencing no disability progression and 89.2% remaining progression-free independent of relapse activity. Patients under 40 had better results than older patients. MAVENCLAD offers lasting benefits without continuous immunosuppression and has been used by over 130,000 patients.